LeMaitre Vascular (NASDAQ:LMAT) Given New $120.00 Price Target at Barrington Research

LeMaitre Vascular (NASDAQ:LMAT) had its price target raised by stock analysts at Barrington Research from $105.00 to $120.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s target price would suggest a potential upside of 8.87% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the company. Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. Wells Fargo & Company raised their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Roth Mkm restated a “buy” rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Finally, Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Down 1.6%

NASDAQ:LMAT traded down $1.78 during mid-day trading on Wednesday, reaching $110.22. The stock had a trading volume of 316,977 shares, compared to its average volume of 205,458. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of 43.91, a price-to-earnings-growth ratio of 3.21 and a beta of 0.60. LeMaitre Vascular has a 1-year low of $78.35 and a 1-year high of $118.01. The stock’s 50 day simple moving average is $109.66 and its two-hundred day simple moving average is $94.33.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm had revenue of $66.55 million for the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter in the prior year, the firm posted $0.48 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities analysts anticipate that LeMaitre Vascular will post 2.89 EPS for the current year.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the sale, the director directly owned 17,979 shares in the company, valued at $1,920,157.20. This trade represents a 32.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider owned 6,677 shares in the company, valued at approximately $736,406.33. This represents a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 215,438 shares of company stock worth $23,062,911. 7.40% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds have recently bought and sold shares of the company. Illinois Municipal Retirement Fund lifted its position in LeMaitre Vascular by 1.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 123 shares during the last quarter. NewEdge Advisors LLC lifted its position in LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 139 shares during the last quarter. State of Alaska Department of Revenue lifted its position in LeMaitre Vascular by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after purchasing an additional 147 shares during the last quarter. Johnson Investment Counsel Inc. lifted its position in LeMaitre Vascular by 0.5% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock valued at $2,607,000 after purchasing an additional 153 shares during the last quarter. Finally, Federated Hermes Inc. lifted its position in LeMaitre Vascular by 0.4% in the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after purchasing an additional 155 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q1 EPS beat and year-over-year growth — LMAT reported $0.68 EPS vs. $0.66 consensus and revenue up 11.1% YoY, showing solid margin performance. This supports the stock’s premium multiple. Article Title
• Positive Sentiment: Management raised guidance — LMAT issued Q2 EPS guidance of $0.79–$0.84 (above Street) and FY26 EPS guidance of $2.93–$3.08 (slightly above consensus), indicating confidence in near-term growth. This is a primary bullish catalyst. Article Title
• Positive Sentiment: Analyst price-target upgrade from Citizens JMP — Citizens JMP raised its target to $127 and moved to “market outperform,” signaling a ~15% upside versus current levels and offering support for the share price. Article Title
• Neutral Sentiment: Quarterly dividend announced — Board declared a $0.25 quarterly dividend (ex-div May 21), a modest yield that may appeal to income-focused investors but is unlikely to materially move the stock. Article Title
• Neutral Sentiment: Earnings call transcript available — Investors can review management’s commentary for color on procedure volumes, margin drivers, and cadence for the rest of 2026. Article Title
• Negative Sentiment: Wells Fargo keeps “equal weight” and trims target — Wells Fargo raised its target to $104 but maintains an equal-weight stance, implying downside versus current levels and signaling some analyst caution that could pressure the stock. Article Title

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.